Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| B cell | 22 studies | 28% ± 8% | |
| plasma cell | 18 studies | 43% ± 15% | |
| naive B cell | 17 studies | 27% ± 8% | |
| plasmablast | 11 studies | 45% ± 23% | |
| memory B cell | 9 studies | 26% ± 6% | |
| non-classical monocyte | 7 studies | 26% ± 9% | |
| astrocyte | 6 studies | 33% ± 10% | |
| macrophage | 6 studies | 26% ± 10% | |
| IgA plasma cell | 5 studies | 35% ± 14% | |
| IgG plasma cell | 5 studies | 28% ± 13% | |
| plasmacytoid dendritic cell | 5 studies | 22% ± 6% | |
| hematopoietic precursor cell | 4 studies | 28% ± 8% | |
| epithelial cell of proximal tubule | 4 studies | 22% ± 4% | |
| immature B cell | 4 studies | 29% ± 9% | |
| dendritic cell | 4 studies | 23% ± 7% | |
| germinal center B cell | 4 studies | 34% ± 12% | |
| conventional dendritic cell | 3 studies | 39% ± 21% | |
| GABAergic neuron | 3 studies | 27% ± 4% | |
| glutamatergic neuron | 3 studies | 34% ± 2% | |
| granulocyte monocyte progenitor cell | 3 studies | 28% ± 12% | |
| hematopoietic stem cell | 3 studies | 20% ± 6% | |
| microglial cell | 3 studies | 21% ± 5% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 28% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 459.74 | 245 / 245 | 100% | 25.40 | 500 / 502 |
| brain | 100% | 167.93 | 2638 / 2642 | 99% | 8.29 | 701 / 705 |
| lung | 99% | 150.36 | 572 / 578 | 99% | 8.68 | 1143 / 1155 |
| breast | 100% | 125.40 | 459 / 459 | 97% | 9.08 | 1081 / 1118 |
| bladder | 100% | 129.33 | 21 / 21 | 94% | 6.84 | 476 / 504 |
| intestine | 99% | 170.14 | 959 / 966 | 94% | 5.37 | 496 / 527 |
| pancreas | 98% | 112.87 | 320 / 328 | 94% | 5.76 | 167 / 178 |
| stomach | 96% | 90.18 | 345 / 359 | 95% | 6.35 | 271 / 286 |
| kidney | 100% | 505.31 | 89 / 89 | 90% | 6.96 | 811 / 901 |
| uterus | 93% | 63.75 | 158 / 170 | 97% | 10.89 | 443 / 459 |
| esophagus | 94% | 73.17 | 1363 / 1445 | 93% | 5.45 | 170 / 183 |
| thymus | 94% | 84.44 | 617 / 653 | 81% | 4.76 | 489 / 605 |
| ovary | 82% | 56.73 | 147 / 180 | 87% | 3.82 | 372 / 430 |
| adrenal gland | 98% | 103.34 | 252 / 258 | 60% | 2.19 | 138 / 230 |
| skin | 69% | 36.98 | 1241 / 1809 | 66% | 4.48 | 311 / 472 |
| liver | 73% | 55.20 | 166 / 226 | 58% | 2.40 | 237 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 71.94 | 29 / 29 |
| spleen | 100% | 765.29 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 14.94 | 45 / 45 |
| adipose | 99% | 111.12 | 1194 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 99% | 103.36 | 1318 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 95% | 74.21 | 765 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 92% | 513.34 | 858 / 929 | 0% | 0 | 0 / 0 |
| heart | 89% | 79.15 | 764 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 9% | 0.40 | 7 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006915 | Biological process | apoptotic process |
| GO_0060770 | Biological process | negative regulation of epithelial cell proliferation involved in prostate gland development |
| GO_0006368 | Biological process | transcription elongation by RNA polymerase II |
| GO_0034243 | Biological process | regulation of transcription elongation by RNA polymerase II |
| GO_0060767 | Biological process | epithelial cell proliferation involved in prostate gland development |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0030308 | Biological process | negative regulation of cell growth |
| GO_0032783 | Cellular component | super elongation complex |
| GO_0016607 | Cellular component | nuclear speck |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0008023 | Cellular component | transcription elongation factor complex |
| GO_0005515 | Molecular function | protein binding |
| GO_0003711 | Molecular function | transcription elongation factor activity |
| Gene name | EAF2 |
| Protein name | ELL-associated factor 2 (Testosterone-regulated apoptosis inducer and tumor suppressor protein) ELL associated factor 2 ELL associated factor 2 (cDNA FLJ60185, highly similar to ELL-associated factor 2) |
| Synonyms | TRAITS BM-040 |
| Description | FUNCTION: Acts as a transcriptional transactivator of TCEA1 elongation activity (By similarity). Acts as a transcriptional transactivator of ELL and ELL2 elongation activities. Potent inducer of apoptosis in prostatic and non-prostatic cell lines. Inhibits prostate tumor growth in vivo. . |
| Accessions | F8WF04 ENST00000490434.5 F8WCI9 ENST00000273668.7 [Q96CJ1-1] Q96CJ1 ENST00000490477.1 ENST00000451944.2 B4DWJ3 |